Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives

Kiaie, Seyed Hossein; Mojarad-Jabali, Solmaz; Khaleseh, Farnaz; Allahyari, Saeideh; Taheri, Elham; Zakeri–Milani, Parvin; Valizadeh, Hadi

doi:10.1016/j.ijpharm.2020.119269

Cited by 66 publications

(30 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosome-liposome hybrids As we know, mRNA and DNA are easily loaded into liposomal structures, but liposomes cannot efficiently transfer these therapeutic cargos to target cells [98]. Unlike liposomes, exosomes are very efficient in delivering their cargo to the cell and releasing them due to their special transmembrane proteins for attaching to the cell and promoting endocytosis [99].…”

Section: Exosome Loadingmentioning

confidence: 99%

Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope

et al. 2021

Self Cite

View full text Add to dashboard Cite

Over the past decade, therapeutic messenger RNAs (mRNAs) have emerged as a highly promising new class of drugs for protein replacement therapies. Due to the recent developments, the incorporation of modified nucleotides in synthetic mRNAs can lead to maximizing protein expression and reducing adverse immunogenicity. Despite these stunning improvements, mRNA therapy is limited by the need for the development of safe and efficient carriers to protect the mRNA integrity for in vivo applications. Recently, leading candidates for in vivo drug delivery vehicles are cell-derived exosomes, which have fewer immunogenic responses. In the current study, the key hurdles facing mRNA-based therapeutics, with an emphasis on recent strategies to overcoming its immunogenicity and instability, were highlighted. Then the immunogenicity and toxicity of exosomes derived from various cell sources were mentioned in detail. Finally, an overview of the recent strategies in using exosomes for mRNA delivery in the treatment of multiple diseases was stated.

show abstract

Section: Exosome Loadingmentioning

confidence: 99%

Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The application and manipulation of biomimetic NPs indicate promising role in CIT such as cellular or molecular agents including high-density lipoproteins (HDL), low-density lipoproteins (LDL) [ 137 ], albumin [ 138 ], and exosome [ 139 ], therefore they can emerge predominant potential in CIT perspective. Likewise, some factors, such as biocompatibility, biodegradability, stability in favor of long-term storage, and intended release profile of payloads and delivery of them to target and administration route, should be considered when choosing a good nanocarrier [ 140 , 141 ].…”

Section: Balancing the Pros And Cons Of Chemoimmunotherapymentioning

confidence: 99%

Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

et al. 2021

Self Cite

View full text Add to dashboard Cite

Nowadays, a potent challenge in cancer treatment is considered the lack of efficacious strategy, which has not been able to significantly reduce mortality. Chemoimmunotherapy (CIT) as a promising approach in both for the first-line and relapsed therapy demonstrated particular benefit from two key gating strategies, including chemotherapy and immunotherapy to cancer therapy; therefore, the discernment of their participation and role of potential synergies in CIT approach is determinant. In this study, in addition to balancing the pros and cons of CIT with the challenges of each of two main strategies, the recent advances in the cancer CIT have been discussed. Additionally, immunotherapeutic strategies and the immunomodulation effect induced by chemotherapy, which boosts CIT have been brought up. Finally, harnessing and development of the nanoparticles, which mediated CIT have expatiated in detail.

show abstract

“…Variations in phospholipids variations are mostly based on the modifications of head group or bondings formed; these are generally categorized according to the backbone groups-glycerol (glycerophospholipids) and sphingosine (sphingomyelins) [68]. These unique lipids are able to encapsulate a wide range of agents owing to their basic molecular structure which is composed of a hydrophilic head (polar head) and two hydrophilic tails (hydrocarbon chains) [68,70,71]. Liposomes are used as carriers for active agents with differing properties in a wide range of applications, such as cosmetics, pharmaceuticals, food, and farming.…”

Section: General Propertiesmentioning

confidence: 99%

“…Liposomes are used as carriers for active agents with differing properties in a wide range of applications, such as cosmetics, pharmaceuticals, food, and farming. The wide-ranging applications of liposomes are attributed to their biocompatibility, encapsulation capability and modifiable formulation for the desired purpose [68][69][70][71][72].…”

Section: General Propertiesmentioning

confidence: 99%

Advances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Recent advancements in nanotechnology have improved our understanding of cancer treatment and allowed the opportunity to develop novel delivery systems for cancer therapy. The biological complexities of cancer and tumour micro-environments have been shown to be highly challenging when treated with a single therapeutic approach. Current co-delivery systems which involve delivering small molecule drugs and short-interfering RNA (siRNA) have demonstrated the potential of effective suppression of tumour growth. It is worth noting that a considerable number of studies have demonstrated the synergistic effect of co-delivery systems combining siRNA and small molecule drugs, with promising results when compared to single-drug approaches. This review focuses on the recent advances in co-delivery of siRNA and small molecule drugs. The co-delivery systems are categorized based on the material classes of drug carriers. We discuss the critical properties of materials that enable co-delivery of two distinct anti-tumour agents with different properties. Key examples of co-delivery of drug/siRNA from the recent literature are highlighted and discussed. We summarize the current and emerging issues in this rapidly changing field of research in biomaterials for cancer treatments.

show abstract

Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives

Cited by 66 publications

References 188 publications

Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope

Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope

Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

Advances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment

Contact Info

Product

Resources

About